The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment strategies for thymic carcinoma in a real-life setting: Insights from the rythmic network.
 
Nicolas Girard
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Pharmamar; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; Roche
 
Arthur Petat
Travel, Accommodations, Expenses - MSD
 
Eric Dansin
No Relationships to Disclose
 
Calcagno Fabien
No Relationships to Disclose
 
Laurent Greillier
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD; Roche
 
Eric Pichon
No Relationships to Disclose
 
Mallorie Kerjouan
No Relationships to Disclose
 
Christelle Clément Duchene
No Relationships to Disclose
 
Bertrand Mennecier
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Pierre Fabre; Roche/Genentech; Vifor Pharma
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD (Inst); novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Expert Testimony - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
 
Virginie Westeel
No Relationships to Disclose
 
Francois Thillays
No Relationships to Disclose
 
Xavier Quantin
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer
 
Marylise Ginoux
No Relationships to Disclose
 
Youssef Oulkhouir
Honoraria - AstraZeneca; MSD Oncology; Roche
Travel, Accommodations, Expenses - Pfizer
 
Luc Thiberville
No Relationships to Disclose
 
Charles Ricordel
No Relationships to Disclose
 
Thierry Molina
No Relationships to Disclose
 
Pierre Fournel
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Pfizer (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Roche
 
Laurence Bigay-Game
No Relationships to Disclose
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst); Tolero Pharmaceuticals (Inst)